In a significant strategy pivot, Walgreens is considering selling its VillageMD primary care subsidiary just three years after purchasing it for $5.2 billion, according to an August 7 SEC filing.
VillageMD clinics provide primary care services, with many locations attached to Walgreens pharmacies. The retail pharmacy chain’s goal when it first bought VillageMD was to get into the value-based care business, which managing partner Michael Abrams at healthcare consulting firm Numerof & Associates previously told Healthcare Brew is a lucrative expansion opportunity for pharmacies.
In the SEC filing, Walgreens executives said they’re “evaluating a variety of options” for VillageMD, which “could include a sale of all or part of the VillageMD businesses, possible restructuring options, and other strategic opportunities.”
Walgreens announced in March that it would close 160 VillageMD clinics following a $6 billion net loss reported in Q2 2024 earnings. Walgreens CEO Tim Wentworth then said in late June that although the company would reduce its stake in VillageMD, it would continue to “believe in [its] future” and “remain an investor and partner,” as Healthcare Brew reported at the time.
Keep reading here.—MA
|